[PDF][PDF] Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a …
Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …
[HTML][HTML] Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: experience from four tertiary centers
Simple Summary Hepatocellular carcinoma is one of the most common cancers in the world
with increasing incidence. In advanced stages, according to the Barcelona Clinic Liver …
with increasing incidence. In advanced stages, according to the Barcelona Clinic Liver …
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Y Hayakawa, K Tsuchiya, M Kurosaki, Y Yasui… - Investigational new …, 2022 - Springer
Background. We aimed to investigate the efficacy and safety of atezolizumab plus
bevacizumab therapy in patients with unresectable hepatocellular carcinoma (u-HCC) …
bevacizumab therapy in patients with unresectable hepatocellular carcinoma (u-HCC) …
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
K Maesaka, R Sakamori, R Yamada, A Doi… - Hepatology …, 2022 - Wiley Online Library
Aim Atezolizumab plus bevacizumab and lenvatinib have each shown efficacy as primary
systemic chemotherapies for hepatocellular carcinoma (HCC) in clinical trials. However …
systemic chemotherapies for hepatocellular carcinoma (HCC) in clinical trials. However …
Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
A Hiraoka, T Kumada, T Tada, M Hirooka… - Cancer …, 2023 - Wiley Online Library
Background/Aim A comparison of therapeutic efficacy between atezolizumab plus
bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable …
bevacizumab (Atez/Bev) and lenvatinib treatment given as first‐line therapy for unresectable …
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis
M Chuma, H Uojima, N Hattori, Y Arase… - Hepatology …, 2022 - Wiley Online Library
Purpose To assess the impact of clinical factors on the safety and efficacy of atezolizumab
plus bevacizumab (ATZ+ BV) treatment in patients with unresectable hepatocellular …
plus bevacizumab (ATZ+ BV) treatment in patients with unresectable hepatocellular …
[HTML][HTML] Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma
Background: Combination therapy with anti-programmed death-ligand 1 monoclonal
antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab …
antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab …
[HTML][HTML] Systemic treatment in intermediate stage (Barcelona Clinic Liver Cancer-B) hepatocellular carcinoma
DS Karagiannakis - Cancers, 2023 - mdpi.com
Simple Summary According to the latest BCLC algorithm, the reference treatment of BCLC-B
HCCs that are non-eligible for surgery or liver transplantation is trans-arterial …
HCCs that are non-eligible for surgery or liver transplantation is trans-arterial …
[HTML][HTML] Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice
Y Ando, T Kawaoka, M Kosaka, Y Shirane, Y Johira… - Cancers, 2021 - mdpi.com
Simple Summary Although atezolizumab plus bevacizumab combination therapy was
approved in September 2020 as the first immune-combined therapy for hepatocellular …
approved in September 2020 as the first immune-combined therapy for hepatocellular …
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials
Y Eso, K Taura, H Seno - Hepatology Research, 2022 - Wiley Online Library
Immunotherapy with immune checkpoint inhibitors has been shown to be beneficial for
cancers originating from various organs. In May 2020, combination therapy with anti …
cancers originating from various organs. In May 2020, combination therapy with anti …